A5091198705- Pancreatic and Hepatic Oncology Research
- Cancer Genomics and Diagnostics
- Renal cell carcinoma treatment
- Pancreatitis Pathology and Treatment
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Neuroendocrine Tumor Research Advances
- Radiation Therapy and Dosimetry
- Gastric Cancer Management and Outcomes
- Advanced Radiotherapy Techniques
- Lung Cancer Research Studies
- Meta-analysis and systematic reviews
- Lung Cancer Diagnosis and Treatment
- Cardiac, Anesthesia and Surgical Outcomes
- Colorectal Cancer Surgical Treatments
St. Antonius Ziekenhuis
2020-2025
University Medical Center Utrecht
2020-2025
Netherlands Comprehensive Cancer Organisation
2024-2025
Cancer Genomics Centre
2020-2025
Utrecht University
2021-2024
Abstract Background Novel definitions suggest that resectability status for pancreatic ductal adenocarcinoma (PDAC) should be assessed beyond anatomical criteria, considering both biological and conditional factors. This has, however, yet to validated on a nationwide scale. study evaluated the prognostic value of factors staging patients with resectable PDAC. Patients Methods A observational cohort was performed, including all consecutive who underwent upfront resection National...
Abstract Background Disease recurrence remains one of the biggest concerns in patients after resection pancreatic ductal adenocarcinoma (PDAC). Despite (neo)adjuvant systemic therapy, most experience local and/or distant PDAC within 2 years. High-level evidence regarding benefits recurrence-focused surveillance is missing, and impact early detection treatment on survival quality life unknown. In European countries, follow-up surgery for currently lacking. Consequently, guidelines...
Introduction of online adaptive MR-guided radiotherapy enables stereotactic body radiation therapy (SBRT) upper abdominal tumors. This study aimed to evaluate the feasibility SBRT on a 1.5 T MR-linac in patients with unresectable malignancies.Patients treated at UMC Utrecht (April 2019 December 2020) were identified prospective 'Multi-OutcoMe EvaluatioN Therapy Using MR-linac' (MOMENTUM) study. Feasibility treatment was arbitrarily defined as an on-table time interval ≤60 min for >75%...
Abstract Background The causal pathway between complications after pancreatic cancer resection and impaired long-term survival remains unknown. aim of this study was to investigate the impact on disease-free interval overall survival, with adjuvant chemotherapy as a mediator. Methods This observational included all patients undergoing in Netherlands (2014–2017). Clinical data were extracted from prospective Dutch Pancreatic Cancer Audit. Recurrence collected additionally. In mediation...
Objective: The aim of the study was to investigate prognostic factors in context neoadjuvant therapy (NAT) and develop tools that can allow for accurate personalized patient prognostication. Summary Background Data: NAT might impact ability well-established clinicopathological resected pancreatic ductal adenocarcinoma (PDAC). Methods: Patients after resection PDAC were identified from Dutch Pancreatic Cancer Group Recurrence Database institutional databases at NYU Langone Health Johns...
To develop a prediction model for long-term (≥5 years) disease-free survival (DFS) after the resection of pancreatic ductal adenocarcinoma (PDAC).Despite high recurrence rates, ~10% patients have DFS PDAC resection. A to predict may aid individualized prognostication and shared decision-making.This nationwide cohort study included all consecutive who underwent in Netherlands (2014-2016). The best-performing prognostic was selected by Cox-proportional hazard analysis Akaike's Information...
Over 80% of patients will develop disease recurrence after radical resection pancreatic ductal adenocarcinoma (PDAC). This study aims to and validate a clinical risk score predicting post-recurrence survival (PRS) at time recurrence.All who had undergoing pancreatectomy for PDAC the Johns Hopkins Hospital or Regional Academic Cancer Center Utrecht during period were included. Cox proportional hazard model was used model. Performance final assessed in test set internal validation.Of 718...
Distinguishing postoperative fibrosis from isolated local recurrence (ILR) after resection of pancreatic ductal adenocarcinoma (PDAC) is challenging. A prognostic model that helps to identify patients at risk ILR can assist clinicians when evaluating patients' imaging. This nationwide study aimed develop a clinically applicable for PDAC resection.
Importance International guidelines lack consistency in their recommendations regarding routine imaging the follow-up after pancreatic resection for ductal adenocarcinoma (PDAC). Consequently, strategies differ between centers worldwide. Objective To compare clinical outcomes, including recurrence-focused treatment and survival, patients with PDAC recurrence who received symptomatic or international affiliated European-African Hepato-Pancreato-Biliary Association (E-AHPBA). Design, Setting,...
Abstract Background Disease recurrence is the main cause of mortality after resection pancreatic ductal adenocarcinoma (PDAC). In 20–30% resected patients, isolated local PDAC occurs. Retrospective studies have suggested that stereotactic body radiation therapy (SBRT) might lead to improved control in these potentially having a beneficial effect on both survival and quality life. The “nationwide randomized controlled trial additional treatment for cancer using therapy” (ARCADE) will...
Objective: To measure the rate of LTS in resected PDAC and determine association between predictors OS LTS. Summary Background Data: Long-term survival (>5 y, LTS) remains rare pancreatic ductal adenocarcinoma (PDAC). Multiple overall (OS) are known but their with unclear. Methods: An international, multicenter retrospective study was conducted. Included were patients from 2012-2019 PDAC. Excluded those metastases at diagnosis or resection, R2 resections, 90-day mortality. Predictors...
The effectiveness of radiotherapy for pancreatic cancer is debated. Patient-derived organoids (PDOs) already mimicked clinical radiation response in other types, which could be valuable as well. This study aimed to investigate whether PDOs can used model RT and explore the presence a dose-response correlation.
Abstract • Background : Disease recurrence is the main cause of mortality after resection pancreatic ductal adenocarcinoma (PDAC). In 20-30% resected patients, isolated local PDAC occurs. Retrospective studies have suggested that stereotactic body radiation therapy (SBRT) might lead to improved control in these potentially having a beneficial effect on both survival and quality life. The “nationwide randomized controlled trial additional treatment for cancer using therapy” (ARCADE) will...